The Role of Exosome-Loaded Hydrogels in Improving Intervertebral Disc Degeneration: A Systematic Review and Meta-Analysis of Preclinical Animal Studies.

IF 3.1 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Bowen Wang, Desheng Xie, Jianming Huang, Zheyuan Huang, Weizong Weng, Danlei Huang, Ying Zhang, Xiaolin Chen
{"title":"The Role of Exosome-Loaded Hydrogels in Improving Intervertebral Disc Degeneration: A Systematic Review and Meta-Analysis of Preclinical Animal Studies.","authors":"Bowen Wang, Desheng Xie, Jianming Huang, Zheyuan Huang, Weizong Weng, Danlei Huang, Ying Zhang, Xiaolin Chen","doi":"10.31083/FBL38302","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Intervertebral disc degeneration (IDD) is a major cause of chronic lower back pain, with current treatment options offering limited efficacy. Exosome-loaded hydrogels have emerged as a promising therapeutic approach due to their biocompatibility and regenerative potential, making them a focus of research for IDD treatment. This study systematically evaluates and performs a meta-analysis of the effectiveness of exosome-loaded hydrogels in preclinical models of IDD.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across four major databases (PubMed, Embase, Cochrane, Web of Science), including animal studies that met predefined criteria. Data extraction and quality assessment were independently performed by two authors. Treatment effects were quantified using standardized mean differences (SMD) with 95% confidence intervals (CI). Outcome measures included disc height index (DHI), magnetic resonance imaging (MRI) grade, histological grade, IDD-related immunohistochemical (IHC) markers (e.g., collagen type II (COL2), matrix metalloproteinase 13 (MMP13)), and aging-related markers (e.g., p16Ink4a-positive cells, p21CIP1A-positive cells).</p><p><strong>Results: </strong>Treatment with exosome-loaded hydrogels significantly enhanced DHI scores at 4 (<i>p</i> = 0.002) and 8 weeks (<i>p</i> < 0.0001), and decreased MRI scores at 8 (<i>p</i> < 0.00001) and 12 weeks (<i>p</i> < 0.0001), and histological assessments. Furthermore, the treatment group exhibited increased COL2 expression at 8 (<i>p</i> = 0.0002) and 12 weeks (<i>p</i> = 0.002), decreased MMP13 levels at 8 (<i>p</i> = 0.0001) and 12 weeks (<i>p</i> = 0.0009), and a reduction in aging markers (p16Ink4a, p21CIP1A, all <i>p</i> < 0.05), suggesting that exosome-loaded hydrogels facilitate intervertebral disc repair through the modulation of molecular pathways. Sensitivity analysis confirmed the robustness of the findings.</p><p><strong>Conclusions: </strong>Exosome-loaded hydrogels show potential for improving the structure and function of intervertebral discs in IDD treatment, potentially slowing degeneration by inhibiting matrix degradation and cellular aging. Further investigation is required to elucidate the underlying mechanisms and to assess the safety and efficacy of these hydrogels for clinical application. The PROSPERO Registration: CRD420250649970 (https://www.crd.york.ac.uk/PROSPERO/view/CRD420250649970).</p>","PeriodicalId":73069,"journal":{"name":"Frontiers in bioscience (Landmark edition)","volume":"30 6","pages":"38302"},"PeriodicalIF":3.1000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in bioscience (Landmark edition)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/FBL38302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Intervertebral disc degeneration (IDD) is a major cause of chronic lower back pain, with current treatment options offering limited efficacy. Exosome-loaded hydrogels have emerged as a promising therapeutic approach due to their biocompatibility and regenerative potential, making them a focus of research for IDD treatment. This study systematically evaluates and performs a meta-analysis of the effectiveness of exosome-loaded hydrogels in preclinical models of IDD.

Methods: A comprehensive literature search was conducted across four major databases (PubMed, Embase, Cochrane, Web of Science), including animal studies that met predefined criteria. Data extraction and quality assessment were independently performed by two authors. Treatment effects were quantified using standardized mean differences (SMD) with 95% confidence intervals (CI). Outcome measures included disc height index (DHI), magnetic resonance imaging (MRI) grade, histological grade, IDD-related immunohistochemical (IHC) markers (e.g., collagen type II (COL2), matrix metalloproteinase 13 (MMP13)), and aging-related markers (e.g., p16Ink4a-positive cells, p21CIP1A-positive cells).

Results: Treatment with exosome-loaded hydrogels significantly enhanced DHI scores at 4 (p = 0.002) and 8 weeks (p < 0.0001), and decreased MRI scores at 8 (p < 0.00001) and 12 weeks (p < 0.0001), and histological assessments. Furthermore, the treatment group exhibited increased COL2 expression at 8 (p = 0.0002) and 12 weeks (p = 0.002), decreased MMP13 levels at 8 (p = 0.0001) and 12 weeks (p = 0.0009), and a reduction in aging markers (p16Ink4a, p21CIP1A, all p < 0.05), suggesting that exosome-loaded hydrogels facilitate intervertebral disc repair through the modulation of molecular pathways. Sensitivity analysis confirmed the robustness of the findings.

Conclusions: Exosome-loaded hydrogels show potential for improving the structure and function of intervertebral discs in IDD treatment, potentially slowing degeneration by inhibiting matrix degradation and cellular aging. Further investigation is required to elucidate the underlying mechanisms and to assess the safety and efficacy of these hydrogels for clinical application. The PROSPERO Registration: CRD420250649970 (https://www.crd.york.ac.uk/PROSPERO/view/CRD420250649970).

外泌体负载水凝胶在改善椎间盘退变中的作用:临床前动物研究的系统回顾和荟萃分析。
目的:椎间盘退变(IDD)是慢性下背部疼痛的主要原因,目前的治疗方案疗效有限。外泌体负载水凝胶由于其生物相容性和再生潜力而成为一种有前景的治疗方法,使其成为IDD治疗的研究热点。本研究系统地评估了外泌体负载水凝胶在IDD临床前模型中的有效性,并进行了荟萃分析。方法:在四个主要数据库(PubMed, Embase, Cochrane, Web of Science)中进行全面的文献检索,包括符合预定义标准的动物研究。数据提取和质量评估由两位作者独立完成。采用标准化平均差(SMD)和95%置信区间(CI)对治疗效果进行量化。结果测量包括椎间盘高度指数(DHI)、磁共振成像(MRI)分级、组织学分级、idd相关免疫组化(IHC)标志物(如胶原II型(COL2)、基质金属蛋白酶13 (MMP13))和衰老相关标志物(如p16ink4a阳性细胞、p21cip1a阳性细胞)。结果:外泌体负载水凝胶治疗显著提高了4周(p = 0.002)和8周(p < 0.0001)的DHI评分,降低了8周(p < 0.00001)和12周(p < 0.0001)的MRI评分和组织学评分。此外,治疗组在8周(p = 0.0002)和12周(p = 0.002)时COL2表达增加,8周(p = 0.0001)和12周(p = 0.0009)时MMP13水平降低,衰老标志物(p16Ink4a, p21CIP1A,均p < 0.05)减少,表明外泌体负载的水凝胶通过调节分子途径促进椎间盘修复。敏感性分析证实了研究结果的稳健性。结论:外泌体负载水凝胶在IDD治疗中显示出改善椎间盘结构和功能的潜力,可能通过抑制基质降解和细胞老化来减缓退变。需要进一步的研究来阐明潜在的机制,并评估这些水凝胶临床应用的安全性和有效性。普洛斯彼罗注册:CRD420250649970 (https://www.crd.york.ac.uk/PROSPERO/view/CRD420250649970)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信